GAA rs1801130: Understanding the c.-32-13T>G Splice Variant
The rs1801130 variant, also known as c.-32-13T>G, is a common genetic alteration in the GAA gene. It is primarily recognized as a 'leaky' splice-site mutation associated with carrier status for late-onset Pompe disease, an autosomal recessive lysosomal storage disorder.
What each genotype means
Typical GAA enzyme activity
This genotype represents the common, functional version of the GAA gene. Individuals with this profile do not carry the specific leaky splice-site mutation associated with late-onset Pompe disease.
This is the most common genotype found in the general population across all ancestries.
Pompe disease carrier status
This genotype indicates you carry one copy of the c.-32-13T>G variant, historically known as IVS1-13T>G. While this variant is associated with late-onset Pompe disease, carriers typically do not exhibit symptoms of the condition, though you should discuss any family history or concerns with a genetic counselor or physician.
Carried by approximately 1 in 250 to 1 in 500 people globally, with higher frequencies observed in non-Finnish European populations.
Potential late-onset Pompe disease
This genotype means you carry two copies of the c.-32-13T>G variant, which causes a splicing defect that reduces GAA enzyme activity to approximately 10-20% of normal levels. This is a known cause of late-onset Pompe disease, a condition characterized by progressive muscle weakness and respiratory issues; please consult a medical specialist for clinical evaluation and diagnostic confirmation.
This genotype is rare in the general population, occurring significantly less frequently than the carrier state.
What is the rs1801130 Variant?
The rs1801130 variant is a specific change in the DNA sequence of the GAA gene, located on chromosome 17. In scientific literature, it is frequently referred to by its legacy name, IVS1-13T>G, or simply as the c.-32-13T>G splice-site mutation. This variant occurs in the non-coding region of the gene, specifically within the acceptor splice site of intron 1. Splice sites are critical 'instructions' that tell the cellular machinery where to cut and join segments of RNA during the process of gene expression. Because this mutation is 'leaky,' it does not completely stop the splicing process. Instead, it allows the cell to produce a small amount of correctly spliced, functional messenger RNA alongside several types of incorrectly spliced, non-functional transcripts. This residual production of functional enzyme is a hallmark of this specific variant.
The Role of the GAA Gene
The GAA gene provides the blueprint for an enzyme called acid alpha-glucosidase, also known as acid maltase. This enzyme resides within lysosomes, which are the recycling centers of the cell. Its primary job is to break down complex sugars, specifically glycogen, into simpler glucose molecules that the body can use for energy. When the GAA gene contains pathogenic mutations, the resulting enzyme may be absent or significantly reduced in activity. This leads to the accumulation of glycogen within lysosomes, particularly in cardiac, skeletal, and smooth muscle tissues. This buildup interferes with normal cellular function and is the underlying cause of Pompe disease, also known as glycogen storage disease type II. The severity of the condition often correlates with the amount of residual enzyme activity produced by the specific mutations present in an individual's genetic code.
Research and Clinical Associations
Research has established a strong association between the rs1801130 variant and late-onset Pompe disease (LOPD). Unlike infantile-onset forms of the disease, which are typically more severe and present with cardiomyopathy, LOPD often manifests later in life with symptoms like progressive muscle weakness and respiratory insufficiency. Because rs1801130 is a 'leaky' mutation, individuals who carry it often retain enough enzyme activity to avoid the most severe, early-onset symptoms. However, when inherited alongside another pathogenic GAA mutation, it can lead to the development of LOPD. It is important to note that there is significant phenotypic heterogeneity, meaning that even among people with the same genotype, the age of onset and the severity of symptoms can vary widely. Clinical diagnosis of Pompe disease requires specialized biochemical testing of enzyme activity and comprehensive genetic analysis, as this variant alone is not a diagnostic tool.
Population Frequency
The rs1801130 variant is notably common in populations of European descent. According to data from the Genome Aggregation Database (gnomAD), the global allele frequency is approximately 0.002, but this frequency rises to about 0.004 in non-Finnish European populations. Because Pompe disease is an autosomal recessive condition, an individual must inherit two pathogenic variants—one from each parent—to be affected. Being a carrier (having one copy of the variant) is generally asymptomatic. Due to its relatively high frequency in certain populations, it is frequently identified during carrier screening programs. The prevalence of this variant underscores the importance of genetic counseling for individuals who are identified as carriers, particularly when planning for family health, as it helps clarify the risk of passing the variant to future generations.
Interpreting Your Genetic Information
If you have received information about your status regarding rs1801130, it is essential to understand what this means in a medical context. This variant is a known carrier marker, but it is not a diagnosis of Pompe disease. Genetic testing results should always be interpreted by a qualified healthcare professional, such as a genetic counselor or a medical geneticist, who can place the findings within the context of your personal and family health history. You cannot use this information to self-diagnose or predict specific health outcomes, as the clinical expression of GAA-related conditions is complex and influenced by other genetic and environmental factors. If you are concerned about your carrier status or potential symptoms, discuss these findings with your clinician. They can provide appropriate guidance, recommend further diagnostic testing if necessary, and help you understand the implications for your health and family planning.
How common is this variant?
The rs1801130 variant has a global allele frequency of approximately 0.002, with higher frequencies reaching up to 0.004 in non-Finnish European populations.
Frequently asked questions
Is rs1801130 a diagnosis for Pompe disease?
No, rs1801130 is a genetic variant associated with carrier status for late-onset Pompe disease. It is not a diagnostic test, and clinical diagnosis requires specialized enzyme activity testing and comprehensive genetic evaluation.
What does it mean to be a carrier of this variant?
Being a carrier means you have one copy of the variant and one typical copy of the gene. Carriers are generally asymptomatic, but they may pass the variant to their children.
Can I have symptoms if I am a carrier?
Typically, carriers of autosomal recessive conditions like Pompe disease do not show symptoms. If you are experiencing muscle weakness or other concerns, you should consult a physician for a full clinical assessment.
Why is this variant called 'leaky'?
It is called 'leaky' because the mutation does not completely block the production of the GAA enzyme. It allows the cell to produce a small amount of functional enzyme, which often results in a milder, late-onset form of the disease.
Sources & further reading
Educational information only, last refreshed 9/27/2026. Not medical advice — these associations describe population statistics, not individual predictions.
Curious what your genotype is for rs1801130?
Upload a raw DNA file from 23andMe, AncestryDNA, MyHeritage, or FamilyTreeDNA and see this variant — plus thousands more — interpreted in your full report.
Get my report — $29